Page last updated: 2024-09-04

ptk 787 and semaxinib

ptk 787 has been researched along with semaxinib in 2 studies

Compound Research Comparison

Studies (ptk 787)	Trials (ptk 787)	Recent Studies (post-2010) (ptk 787)	Studies (semaxinib)	Trials (semaxinib)	Recent Studies (post-2010) (semaxinib)
5	0	1	480	31	218

Protein Interaction Comparison

Protein	Taxonomy	semaxinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	Homo sapiens (human)	0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	Homo sapiens (human)	0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET	Homo sapiens (human)	0.17
Dihydrofolate reductase	Homo sapiens (human)	2.4
Dihydrofolate reductase	Mus musculus (house mouse)	2.4
Epidermal growth factor receptor	Homo sapiens (human)	3.592
Platelet-derived growth factor receptor beta	Mus musculus (house mouse)	4.05
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	0.084
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	0.17
Neuronal acetylcholine receptor subunit alpha-4	Rattus norvegicus (Norway rat)	0.5
Platelet-derived growth factor receptor beta	Homo sapiens (human)	2.3563
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	0.365
Fibroblast growth factor receptor 1	Homo sapiens (human)	4.865
Neuronal acetylcholine receptor subunit beta-2	Rattus norvegicus (Norway rat)	0.5
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	3.89
Dihydrofolate reductase	Pneumocystis carinii	2.4
Platelet-derived growth factor receptor alpha	Homo sapiens (human)	0.2
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	0.7648
Fibroblast growth factor receptor 2	Homo sapiens (human)	5
Fibroblast growth factor receptor 4	Homo sapiens (human)	5
Fibroblast growth factor receptor 3	Homo sapiens (human)	5
Platelet-derived growth factor receptor alpha	Mus musculus (house mouse)	4.05
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	0.275
Vascular endothelial growth factor receptor 2	Mus musculus (house mouse)	1.04
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	1.0999
Vascular endothelial growth factor receptor 1	Mus musculus (house mouse)	1.04
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	0.16
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	0.2
Vascular endothelial growth factor receptor 2	Danio rerio (zebrafish)	0.068
1,25-dihydroxyvitamin D-3 receptor	Sus scrofa domesticus (domestic pig)	1.04
Dihydrofolate reductase	Rattus norvegicus (Norway rat)	2.4
ALK tyrosine kinase receptor	Homo sapiens (human)	1.505

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B	1
Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J	1

Other Studies

2 other study(ies) available for ptk 787 and semaxinib

Article	Year
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. Journal of medicinal chemistry, 2000, Jun-15, Volume: 43, Issue:12 Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1	2000
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26 Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor	2002

Article

Year

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

Journal of medicinal chemistry, 2000, Jun-15, Volume: 43, Issue:12

Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1

2000

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26

Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor

2002